Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma

In an engaging discussion, Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, share how they currently treat patients with cholangiocarcinoma, including initial diagnosis, biomarker testing to guide treatment, adverse event management, and patient counseling.
Christine Chio, PharmD, BCOP
Lipika Goyal, MD
Caroline Kuhlman, NP
Released: March 21, 2022

In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include:

  • Initial diagnosis
  • Biomarker testing to guide treatment with immunotherapies and targeted agents
  • Adverse event management
  • Strategies for counseling patients

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Incyte Corporation

Information on this Educational Activity

Faculty

Christine Chio, PharmD, BCOP

Clinical Ambulatory GI Oncology Pharmacist
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts

Christine Chio, PharmD, BCOP, has no relevant conflicts of interest to disclose.
Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Lipika Goyal, MD, has received funds for research paid to her institution from Adaptimmune, Bayer, Bristol Meyers Squibb, Eisai, Genentech, Merck, Incyte, Leap Therapeutics, Lilly, Loxo Oncology, Macrogenics, Novartis, NuCana, QED, Relay Therapeutics, Servier, and Taiho; consultant/advisory fees from Alentis, Black Diamond, Genentech, Exelixis, H3 Biomedicine, Incyte, QED, Servier, Sirtex, and Taiho; and funds as a part of the Data Safety Monitoring Committee for AstraZeneca.
Caroline Kuhlman, NP

Nurse Practitioner
GI Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Caroline Kuhlman, NP has no relevant conflicts of interest to disclose.

Program Medium

This program has been made available online.

Related Content

Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 13, 2022

CAIRO5: FOLFOXIRI + bevacizumab vs FOLFOX/FOLFIRI + bevacizumab in initially unresectable colorectal liver metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings